34 related articles for article (PubMed ID: 38581722)
1. Determination of valsartan and pitavastatin using synchronous spectrofluorimetry and augmented least squares chemometric models: A comparative study with greenness and blueness assessment.
Almalki AH; Abduljabbar MH; Alzhrani RM; Alosaimi ME; Serag A
Luminescence; 2024 Jun; 39(6):e4803. PubMed ID: 38880967
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of daclatasvir in Egyptian adolescents with genotype-4 HCV infection.
Al-Nahari MM; Abbassi MM; Ebeid FS; Hassany M; El-Sayed MH; Farid SF
Antivir Ther; 2020; 25(2):101-110. PubMed ID: 32367815
[TBL] [Abstract][Full Text] [Related]
3. Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease.
Lawitz E; Poordad F; Gutierrez JA; Kakuda TN; Picchio G; Beets G; Vandevoorde A; Van Remoortere P; Jacquemyn B; Luo D; Ouwerkerk-Mahadevan S; Vijgen L; Van Eygen V; Beumont M
J Viral Hepat; 2017 Apr; 24(4):287-294. PubMed ID: 27878906
[TBL] [Abstract][Full Text] [Related]
4. Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons.
Mastrorosa I; Tempestilli M; Notari S; Lorenzini P; Fabbri G; Grilli E; Bellagamba R; Vergori A; Cicalini S; Ammassari A; Agrati C; Antinori A
Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):135-142. PubMed ID: 34623616
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
Sulkowski MS; Feld JJ; Lawitz E; Felizarta F; Corregidor AM; Khalid O; Ghalib R; Smith WB; Van Eygen V; Luo D; Vijgen L; Gamil M; Kakuda TN; Ouwerkerk-Mahadevan S; Van Remoortere P; Beumont M
J Viral Hepat; 2018 Jun; 25(6):631-639. PubMed ID: 29274193
[TBL] [Abstract][Full Text] [Related]
6. HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.
Dahari H; Canini L; Graw F; Uprichard SL; Araújo ES; Penaranda G; Coquet E; Chiche L; Riso A; Renou C; Bourliere M; Cotler SJ; Halfon P
J Hepatol; 2016 Jun; 64(6):1232-9. PubMed ID: 26907973
[TBL] [Abstract][Full Text] [Related]
7. Synchronous spectrofluorimetry and chemometric modeling: A synergistic approach for analyzing simeprevir and daclatasvir, with application to pharmacokinetics evaluation.
Serag A; Alnemari RM; Abduljabbar MH; Alosaimi ME; Almalki AH
Spectrochim Acta A Mol Biomol Spectrosc; 2024 Jul; 315():124245. PubMed ID: 38581722
[TBL] [Abstract][Full Text] [Related]
8. Daclatasvir for the treatment of chronic hepatitis C virus infection.
Temesgen Z; Rizza SA
Drugs Today (Barc); 2015 May; 51(5):277-88. PubMed ID: 26097901
[TBL] [Abstract][Full Text] [Related]
9. Daclatasvir: a review of its use in adult patients with chronic hepatitis C virus infection.
McCormack PL
Drugs; 2015 Apr; 75(5):515-24. PubMed ID: 25721433
[TBL] [Abstract][Full Text] [Related]
10. Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.
Smith MA; Regal RE; Mohammad RA
Ann Pharmacother; 2016 Jan; 50(1):39-46. PubMed ID: 26486762
[TBL] [Abstract][Full Text] [Related]
11. Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A.
Gentile I; Borgia F; Coppola N; Buonomo AR; Castaldo G; Borgia G
Curr Med Chem; 2014; 21(12):1391-404. PubMed ID: 24372205
[TBL] [Abstract][Full Text] [Related]
12. HCV direct-acting antiviral agents: the best interferon-free combinations.
Schinazi R; Halfon P; Marcellin P; Asselah T
Liver Int; 2014 Feb; 34 Suppl 1(Suppl 1):69-78. PubMed ID: 24373081
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
